Financial Enhancement Group LLC Acquires Shares of 28,002 Inari Medical, Inc. (NASDAQ:NARI)

Financial Enhancement Group LLC bought a new stake in shares of Inari Medical, Inc. (NASDAQ:NARI - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 28,002 shares of the company's stock, valued at approximately $1,155,000.

Other large investors have also recently made changes to their positions in the company. Motley Fool Asset Management LLC increased its position in shares of Inari Medical by 46.2% during the 1st quarter. Motley Fool Asset Management LLC now owns 64,677 shares of the company's stock valued at $3,103,000 after purchasing an additional 20,438 shares during the last quarter. Bamco Inc. NY increased its holdings in Inari Medical by 27.4% in the 1st quarter. Bamco Inc. NY now owns 777,152 shares of the company's stock worth $37,288,000 after acquiring an additional 167,000 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new stake in Inari Medical in the 2nd quarter worth about $2,145,000. Integral Health Asset Management LLC increased its holdings in Inari Medical by 100.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company's stock worth $19,260,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Seven Eight Capital LP purchased a new stake in Inari Medical in the 1st quarter worth about $499,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

Inari Medical Trading Down 2.7 %

Shares of NASDAQ NARI traded down $1.43 during midday trading on Thursday, hitting $51.84. 899,737 shares of the company's stock were exchanged, compared to its average volume of 1,000,236. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $67.13. The company has a market cap of $3.03 billion, a price-to-earnings ratio of -39.46 and a beta of 0.96. The business's fifty day moving average price is $44.10 and its two-hundred day moving average price is $46.35.

Insider Transactions at Inari Medical

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company's stock, valued at $22,265,500. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Inari Medical news, CFO Mitch C. Hill sold 5,000 shares of the company's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $47.99, for a total value of $239,950.00. Following the completion of the sale, the chief financial officer now owns 179,600 shares of the company's stock, valued at $8,619,004. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 445,310 shares of the company's stock, valued at approximately $22,265,500. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 131,000 shares of company stock valued at $6,161,340. 10.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

NARI has been the subject of several recent research reports. William Blair initiated coverage on Inari Medical in a report on Thursday, July 25th. They issued an "outperform" rating for the company. Stifel Nicolaus initiated coverage on Inari Medical in a report on Tuesday, September 17th. They issued a "hold" rating and a $50.00 price objective for the company. Leerink Partners began coverage on Inari Medical in a report on Tuesday, September 3rd. They issued a "market perform" rating and a $47.00 price objective for the company. Robert W. Baird raised their target price on Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 29th. Finally, Needham & Company LLC restated a "hold" rating on shares of Inari Medical in a research note on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $58.89.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.